Compare CNXU & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXU | RXST |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.4M | 232.2M |
| IPO Year | N/A | 2021 |
| Metric | CNXU | RXST |
|---|---|---|
| Price | $7.76 | $6.29 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $9.78 |
| AVG Volume (30 Days) | 134.1K | ★ 1.0M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $134,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.10 | $4.48 |
| 52 Week High | $13.66 | $13.22 |
| Indicator | CNXU | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 36.73 | 64.83 |
| Support Level | $7.62 | $5.90 |
| Resistance Level | $11.51 | $6.53 |
| Average True Range (ATR) | 1.25 | 0.38 |
| MACD | -0.08 | 0.10 |
| Stochastic Oscillator | 9.91 | 98.31 |
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.